ARS Pharmaceuticals (SPRY) Enterprise Value (2022 - 2026)

ARS Pharmaceuticals has reported Enterprise Value for 7 years, with the latest figure at -$201.0 million in Q1 2026.

• Quarterly Enterprise Value rose 27.11% year-over-year to -$201.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201.0 million (up 27.11% YoY) and the FY2025 annual result came in at -$245.0 million, up 21.98% from the prior year.
• Enterprise Value advanced to -$201.0 million in Q1 2026 per SPRY's latest filing, from -$245.0 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$201.0 million in Q1 2026 and troughed at -$314.0 million in Q4 2024.
• A 5-year average of -$250.1 million and a median of -$252.2 million in 2023 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 32.16% in 2022, down 356.82% in 2022.
• Over 5 years, Enterprise Value stood at -$274.4 million in 2022, then increased by 16.77% to -$228.4 million in 2023, then sank by 37.51% to -$314.0 million in 2024, then climbed by 21.98% to -$245.0 million in 2025, then advanced by 17.97% to -$201.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$201.0 million, -$245.0 million, and -$288.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.